Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

Building consents stabilising but no immediate recovery
Markets

Building consents stabilising but no immediate recovery

Housing consents rose 4.8% on year in November but fall 12% for 12-month period. 

Beyond the glitter: Can gold hedge against a falling NZ dollar?
Markets

Beyond the glitter: Can gold hedge against a falling NZ dollar?

Gold gained 42% in NZ dollar terms last year, its value helped by falling interest rates.

Market ends week down but Briscoe defies guidance
Markets Market close

Market ends week down but Briscoe defies guidance

The S&P/NZX 50 Index is down 1.5% since the beginning of the year.

Graham Skellern 10 Jan 2025